SCHEMBL1179519

SCHEMBL1179519

Cc1cc(C#N)nc(Cl)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.49
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
FFAR1 O14842 1/20 0.40
ALDH1A1 P00352 6/20 0.37
HTT P42858 1/20 0.37
HPGD P15428 2/20 0.37
PPARG P37231 1/20 0.37
STAT3 P40763 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
NR2E3 Q9Y5X4 1/20 0.37
NCOR2 Q9Y618 1/20 0.37
TSHR P16473 2/20 0.34
HSD17B10 Q99714 1/20 0.34
POLB P06746 2/20 0.33
MAPT P10636 2/20 0.33
MAPK1 P28482 1/20 0.33
CACNA1B Q00975 1/20 0.33
APBA1 Q02410 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19295125 0.84 KDM4E (0.52) KDM4EMEN1KMT2AALDH1A1HPGD
SCHEMBL2333650 0.78 KDM4E (0.40) KDM4EMEN1KMT2AALDH1A1HPGD
SCHEMBL30816543 0.78 KDM4E (0.40) KDM4EMEN1KMT2AALDH1A1HPGD
SCHEMBL4917689 0.77 GPR119 (0.42) KDM4EMEN1KMT2AALDH1A1HPGD
SCHEMBL17608843 0.77 KDM4E (0.47) KDM4EALDH1A1HPGDTSHRMAPT
SCHEMBL21614634 0.76 KDM4E (0.39) KDM4EMEN1KMT2AALDH1A1HTT
SCHEMBL390428 0.75
SCHEMBL10692686 0.74 POLB (0.49) KDM4EALDH1A1HPGDPPARGSTAT3
SCHEMBL22389992 0.74 KDM4E (0.45) KDM4EALDH1A1HTTHPGDPPARG
SCHEMBL23671230 0.74 KDM4E (0.45) KDM4EALDH1A1HPGDHSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025224512-A1 NOVEL COMPOUND AS 17-BETA-HYDROXYSTEROID DEHYDROGENASE 13 (HSD17B13) INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME 삼진제약주식회사 2025-10-30 WO disclosed
US-20250250264-A1 KIF18A INHIBITOR AND USE THEREOF Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) 2025-08-07 US disclosed
US-20250223280-A1 POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS AVILAR THERAPEUTICS, INC. (US) 2025-07-10 US disclosed
US-12312340-B2 Potent ASGPR-binding compounds for the degradation of immunoglobulins and other proteins AVILAR THERAPEUTICS, INC. (US) 2025-05-27 US disclosed
WO-2025085848-A1 ANTIBACTERIAL COMPOUNDS ARREPATH, INC. (US) 2025-04-24 WO disclosed
CN-115916765-B Pyridine or pyrimidine derivative and preparation method and application thereof 浙江海正药业股份有限公司 2025-04-18 CN disclosed
EP-4524136-A1 KINESIN KIF18A INHIBITOR AND USE THEREOF Shanghai Apeiron Therapeutics Company Limited (CN) 2025-03-19 EP disclosed
WO-2025054132-A1 ANTIBACTERIAL COMPOUNDS ARREPATH, INC. (US) 2025-03-13 WO disclosed
EP-4509505-A1 KIF18A INHIBITOR AND USE THEREOF Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) 2025-02-19 EP disclosed
CN-113795483-B Carboxamide-pyrimidine derivatives as SHP2 antagonists 默克专利有限公司 2024-12-31 CN disclosed
US-20170320876-A1 BRIDGED DIAZEPANE OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2017-11-09 US disclosed
US-20170320876-A1 BRIDGED DIAZEPANE OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2017-11-09 US disclosed
WO-2016085783-A1 BRIDGED DIAZEPANE OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2016-06-02 WO disclosed
US-20110046170-A1 NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2011-02-24 US disclosed
CN-101965346-A Novel pyrimidine-pyridine derivatives ACTELION PHARMACEUTICALS LTD 2011-02-02 CN disclosed
EP-2262800-A1 NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2010-12-22 EP disclosed
WO-2009109907-A1 NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-09-11 WO disclosed
US-5759956-A PYRAZINE CARBOXAMIDE DERIVATIVES AMERICAN CYANAMID COMPANY (US) 1998-06-02 US disclosed
EP-0700391-A1 HERBICIDAL COMPOUNDS SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1996-03-13 EP disclosed
WO-1994027974-A1 HERBICIDAL COMPOUNDS SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. (NL) 1994-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12312340-B2 Potent ASGPR-binding compounds for the degradation of immunoglobulins and other proteins ASGR1, FCGR2A, FCGR3B KDM4E 4104/4885MEN1 4089/4885KMT2A 4639/4885
US-20250223280-A1 POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS ASGR1, FCGR2A, FCGR3B KDM4E 4104/4885MEN1 4089/4885KMT2A 4639/4885
US-20110046170-A1 NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES TYMP, DPYD, ENTPD5 KDM4E 1861/4885MEN1 4570/4885KMT2A 3361/4885
US-20250250264-A1 KIF18A INHIBITOR AND USE THEREOF KIF18A, KIF18B, KIF15 KDM4E 1075/4885MEN1 1762/4885KMT2A 141/4885
US-20170320876-A1 BRIDGED DIAZEPANE OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, CRHR1 KDM4E 1930/4885MEN1 1533/4885KMT2A 917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.